FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASPIRE Trial To KYPROLIS ® (carfilzomib) Label
KYPROLIS, Lenalidomide and Dexamethasone Extended Median Overall Survival in Relapsed or Refractory Multiple Myeloma Patients to 48 Months KYPROLIS is the First and Only Treatment to Demonstrate Overall Survival Benefits in Two Phase 3 Studies in Relapsed or Refractory Multiple Myeloma THOUSAND OAKS, Calif., June 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add the positive overall survival (OS) data from the Phase 3 ASPIRE trial to the U.S. Prescribing Information for KYPROLIS® (car...
Source: Amgen News Release - June 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

PharmaMar presents at ASCO the ADMYRE study's adjusted overall survival with plitidepsin
(Pharmamar) PharmaMar (MSE:PHM) has presented today how crossover has had an influence on the overall survival of the ADMYRE trial. The impact on overall survival of those patients that relapsed after receiving dexamethasone as a single agent and who were subsequently treated with plitidepsin in combination with dexamethasone was analyzed. Of the 84 patients treated from the comparator arm -dexamethasone as a single agent- 44 percent, 37 patients were treated with the combination with plitidepsin thereafter. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 5, 2018 Category: Cancer & Oncology Source Type: news

Once-Weekly Bests Twice-Weekly Carfilzomib in R/R Multiple Myeloma
Leah LawrenceJun 2, 2018A once-weekly regimen of carfilzomib plus dexamethasone improved response and delayed progression better than a twice-weekly regimen in R/R MM. (Source: CancerNetwork)
Source: CancerNetwork - June 2, 2018 Category: Cancer & Oncology Authors: A Source Type: news

Phase 3 A.R.R.O.W. Interim Analysis Shows Once-Weekly 70 mg/m2 KYPROLIS ® (carfilzomib) Regimen Significantly Extended Progression-Free Survival Versus A Twice-Weekly 27 mg/m2 Regimen In Patients With Relapsed And Refractory Multiple Myeloma
Less Frequent Once-Weekly KYPROLIS Regimen Also Significantly Increased Overall Response Rates With a Comparable Safety Profile Versus a Twice-Weekly Regimen Prespecified Interim Analysis Presented Today During Oral Session at ASCO 2018 and Simultaneously Published in The Lancet Oncology THOUSAND OAKS, Calif., June 1, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 3 A.R.R.O.W. trial of a once-weekly KYPROLIS® (carfilzomib) dosing regimen in patients with relapsed and refractory multiple myeloma. In the trial, KYPROLIS administered once-weekly at 70 mg/m2 with dexamethasone (once-...
Source: Amgen News Release - June 1, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive CHMP Opinion To Add Overall Survival Results From The Phase 3 ASPIRE Study To KYPROLIS ® (carfilzomib) Label
KYPROLIS is the First and Only Relapsed or Refractory Multiple Myeloma Treatment to Demonstrate Overall Survival in two Phase 3 Studies THOUSAND OAKS, Calif., April 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include the final overall survival (OS) data from the Phase 3 ASPIRE trial. The ASPIRE trial demonstrated that the addition of KYPROLIS to lenalidomide and dexamethasone (KRd) reduced the risk of deat...
Source: Amgen News Release - April 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Duel of the inflammatory master regulators: Insights for drug discovery
(Emory Health Sciences) Anti-inflammatory drugs such as dexamethasone can have harmful side effects on the skin, bones and metabolism. Emory structural biology research has implications for the long-standing quest to separate these drugs' benefits from their side effects. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2018 Category: International Medicine & Public Health Source Type: news

A Novel Combination Therapy for Refractory Multiple Myeloma A Novel Combination Therapy for Refractory Multiple Myeloma
Dexamethasone can be problematic for patients with diabetes. The authors developed a novel dexamethasone-free combination regimen for multiple myeloma, which proved effective in this diabetic patient.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2018 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Is the Use of Dexamethasone Effective in Controlling Pain Associated with Symptomatic Irreversible Pulpitis? A Systematic Review
This study was registered in the PROSPERO database (CRD42017058704), and Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement recommendations were followed. MEDLINE, Scopus, ScienceDirect, Web of Science, Latin American Caribbean Health Sciences Literature, Cochrane Library, and Google Scholar databases were used in our research. No restrictions were applied to dates or language of publication. All records identified electronically were organized and evaluated by 2 independent authors, and, in case of doubt, a third author made the decision. The Cochrane Collaboration tool was used. The data were an...
Source: Dental Technology Blog - April 2, 2018 Category: Dentistry Source Type: news

pSivida buys Icon Bioscience and rebrands as EyePoint Pharmaceuticals
With the help of $61 million from EW Healthcare Partners and a third-party investor, pSivida (NSDQ:PSDV) announced today that it acquired Icon Bioscience and its FDA-approved dexamethasone intraocular suspension designed to treat postoperative inflammation. The two companies combined and plan to do business as EyePoint Pharmaceuticals. pSivida also landed a $20 million debt facility from SWK Holdings Corp., to help fund the Icon buyout and prepare for the commercial launch of Icon’s Dexycu product. Get the full story at our sister site, Drug Delivery Business News. The post pSivida buys Icon Biosc...
Source: Mass Device - March 29, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Food & Drug Administration (FDA) Mergers & Acquisitions Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat iconbioscience pSivida Corp. Source Type: news

Ixazomib Triplet Combo Effective in R/R Myeloma
The oral therapy combination of ixazomib, pomalidomide, and dexamethasone was effective and well-tolerated in patients with myeloma that had relapsed or was refractory to lenalidomide. (Source: CancerNetwork)
Source: CancerNetwork - March 8, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Immuno Oncology Multiple Myeloma News Source Type: news

Pomalidomide/Dexamethasone Effective in R/R Myeloma With Renal Insufficiency
Nearly 80% of R/R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination. (Source: CancerNetwork)
Source: CancerNetwork - February 28, 2018 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma Source Type: news

Dexycu (Dexamethasone Intraocular Suspension 9%, for Intraocular Administration) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 14, 2018 Category: Drugs & Pharmacology Source Type: news

Icon Bioscience Receives FDA Approval for Dexycu (dexamethasone intraocular suspension) for Treating Inflammation Associated With Cataract Surgery
Newark, CA (February 12, 2018) – Icon Bioscience, Inc. (IBI), a specialty biopharmaceutical company focused on utilizing its Verisome® drug-delivery platform to develop unique intraocular eye-care therapeutics, today announced that the United... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 12, 2018 Category: Drugs & Pharmacology Source Type: news

Do Corticosteroids Improve Diabetic Macular Edema Outcomes? Do Corticosteroids Improve Diabetic Macular Edema Outcomes?
Drs Matt Starr and Sophie Bakri on a randomized trial studying the value of adding intravitreal dexamethasone to anti-VEGF therapy.Medscape Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 30, 2018 Category: Consumer Health News Tags: Ophthalmology Viewpoint Source Type: news

Amgen Receives CHMP Positive Opinion To Add Updated Overall Survival Data To KYPROLIS ® (carfilzomib) Label
Label Variation to Include Overall Survival Data From Phase 3 ENDEAVOR Trial THOUSAND OAKS, Calif., Jan. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending a label variation for KYPROLIS® (carfilzomib) to include updated overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in patients with relapsed or refractory multiple myeloma (KYPROLIS and dexamethasone [Kd] versus Velcade® [bortezomib] and dexamethasone [Vd]). The ENDEAVOR trial ...
Source: Amgen News Release - January 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Addition Of Overall Survival Data To KYPROLIS ® (carfilzomib) Label
Phase 3 Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Velcade® (Bortezomib) and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma Overall Survival Results Support Use of KYPROLIS in Combination With Dexamethasone as New Standard of Care THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) to add overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial to the Prescribing Information for KYPROLIS&re...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Overall Survival Analysis From KYPROLIS ® (Carfilzomib) Phase 3 ASPIRE Trial Published in the Journal of Clinical Oncology
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone in Patients With Relapsed or Refractory Multiple Myeloma Results Support Early Use of KYPROLIS at First Relapse THOUSAND OAKS, Calif., Jan. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology published positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial, which demonstrated that the addition of KYPROLIS® (carfilzomib) to lenalidomide and dexamethasone (KRd) reduced the risk of death by 21 percent ver...
Source: Amgen News Release - January 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Comparison of Effect of Oral Premedication with Ibuprofen or Dexamethasone on Anesthetic Efficacy of Inferior Alveolar Nerve Block in Patients with Irreversible Pulpitis: A Prospective, Randomized, Controlled, Double-blind Study.
Bull Tokyo Dent Coll. 2017;58(4):231-236. doi: 10.2209/tdcpublication.2016-0050.AbstractThe purpose of this prospective, randomized, double-blind, placebo-controlled study was to determine the effect of preoperative oral administration of ibuprofen or dexamethasone on the success rate of inferior alveolar nerve block (IANB) in patients with symptomatic irreversible pulpitis. Seventy-eight patients with irreversible pulpitis were randomly divided into 3 groups (26 per group) and given one of the following at 1 hr prior to performing local anesthesia: a placebo; 400 mg ibuprofen; or 4 mg dexamethasone. Each patient recorded ...
Source: Dental Technology Blog - December 28, 2017 Category: Dentistry Source Type: news

Rolapitant-Based Antiemetic Combination Improves CINV Symptoms
Rolapitant plus 5-HT3 receptor antagonist and dexamethasone is well tolerated and more effectively controls chemotherapy-induced nausea and vomiting compared with 5-HT3 and dexamethasone alone. (Source: CancerNetwork)
Source: CancerNetwork - December 14, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Nausea and Vomiting News Source Type: news

pSivida touts pilot osteoarthritis trial for Durasert implant
pSivida (NSDQ:PSDV) touted results today from a Phase I safety and efficacy pilot trial of its sustained-release Durasert implant in patients with osteoarthritis of the knee. The company’s Durasert tech, combined with an implantable device from the Hospital for Special Surgery, was designed to continuously deliver a low dose of dexamethasone into the knee joint. Six patients with osteoarthritis of the knee were followed throughout the study for six months. Get the full story at our sister site, Drug Delivery Business News. The post pSivida touts pilot osteoarthritis trial for Durasert implant appeared first...
Source: Mass Device - December 14, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Implants Orthopedics Pharmaceuticals Wall Street Beat pSivida Corp. Source Type: news

Combo Antiemetic Therapy Safe, Effective for Testicular Cancer Patients on Cisplatin Chemotherapy
Researchers found that combining palonosetron, aprepitant, and dexamethasone represents an effective and well-tolerated treatment to prevent CINV in testicular cancer patients receiving cisplatin. (Source: CancerNetwork)
Source: CancerNetwork - December 13, 2017 Category: Cancer & Oncology Authors: Bryant Furlow Tags: Genitourinary Cancers Nausea and Vomiting News Testicular Cancer Source Type: news

KYPROLIS ® (carfilzomib) Extended Overall Survival In Patients With Relapsed Or Refractory Multiple Myeloma In Phase 3 ASPIRE Trial
Results Highlighted During Oral Presentation at ASH 2017 Addition of KYPROLIS to Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Alone Regulatory Applications Submitted in the U.S. to add ASPIRE Overall Survival Results to KYPROLIS Label THOUSAND OAKS, Calif., Dec. 11, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced new results showing the positive overall survival (OS) findings from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint of OS, demonstrating that the addition of KYPROLIS® (carfilzomib)...
Source: Amgen News Release - December 11, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

PharmaMar presents positive results of the pivotal Phase III trial with plitidepsin in MM
(Pharmamar) As previously informed, the Phase III trial, ADMYRE, which compared plitidepsin in combination with dexamethasone versus dexamethasone alone met its primary endpoint, progression free survival, and secondary objectives, overall survival and safety (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 11, 2017 Category: International Medicine & Public Health Source Type: news

Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema Dexamethasone Does Not Improve Vision in Persistent Diabetic Macular Edema
Adding dexamethasone to continued ranibizumab treatment reduces retinal thickness but does not improve vision in patients with persistent diabetic macular edema (DME), according to results from a phase 2 randomized trial.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 20, 2017 Category: Consumer Health News Tags: Medscape Today News Source Type: news

iVeena finishes pilot trial of sustained-release implant
iVeena Delivery Systems said earlier this month that it finished a pilot trial for its IVMED-10 bioerodible implant designed to treat pain and inflammation after cataract surgery. Placed during cataract surgery, the sustained-release implant delivers dexamethasone for two weeks from the lens capsule. Get the full story at our sister site, Drug Delivery Business News. The post iVeena finishes pilot trial of sustained-release implant appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - November 17, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pain Management Pharmaceuticals Surgical iveenadeliverysystems Source Type: news

Maxidex Ointment (Dexamethasone Sodium Phosphate Ophthalmic) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 15, 2017 Category: Drugs & Pharmacology Source Type: news

Maxidex Suspension (Dexamethasone Ophthalmic Suspension) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 15, 2017 Category: Drugs & Pharmacology Source Type: news

Perineural vs Systemic Dexamethasone After Nerve Block Perineural vs Systemic Dexamethasone After Nerve Block
Does perineural administration of dexamethasone provide an advantage over systemic administration as an adjunct to local anesthetic for peripheral nerve block?British Journal of Anaesthesia (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 1, 2017 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Prednisone vs. Dexamethasone
Title: Prednisone vs. DexamethasoneCategory: MedicationsCreated: 10/31/2017 12:00:00 AMLast Editorial Review: 10/31/2017 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - October 31, 2017 Category: Drugs & Pharmacology Source Type: news

Allergan ’ s intravitreal implant wins approval in China
Allergan (NYSE:AGN) said today that it landed an imported drugs license from the Chinese FDA to market its dexamethasone intravitreal implant, Ozurdex, as a treatment for adults with macular edema following branch retinal vein occlusion or central retinal vein occlusion. The Dublin-based pharma giant touted its therapy as the first intravitreal injection approved for RVO in China. Get the full story at our sister site, Drug Delivery Business News. The post Allergan’s intravitreal implant wins approval in China appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 30, 2017 Category: Medical Devices Authors: Sarah Faulkner Tags: Drug-Device Combinations Implants Optical/Ophthalmic Pharmaceuticals Regulatory/Compliance Wall Street Beat Allergan Inc. Source Type: news

Phase 3 A.R.R.O.W. Study Of Once-Weekly KYPROLIS ® (Carfilzomib) Regimen Meets Primary Endpoint Of Progression-Free Survival In Relapsed And Refractory Multiple Myeloma Patients
Once-Weekly KYPROLIS at 70 mg/m2 Shows Superior Efficacy and Comparable Safety to Twice-Weekly KYPROLIS at 27 mg/m2 Positive Results From Pre-Specified Interim Analysis THOUSAND OAKS, Calif., Oct. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced top-line results of the Phase 3 A.R.R.O.W. trial, which showed KYPROLIS® (carfilzomib) administered once-weekly at the 70 mg/m2 dose with dexamethasone allowed relapsed and refractory multiple myeloma patients to live 3.6 months longer without their disease worsening than KYPROLIS administered twice-weekly at the 27 mg/m2 dose with dexamethasone. The ov...
Source: Amgen News Release - October 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Dexamethasone/Povidone-Iodine Effective for Conjunctivitis Dexamethasone/Povidone-Iodine Effective for Conjunctivitis
The experimental combination led to clinical resolution and viral eradication in a randomized, controlled phase 2 trial.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 12, 2017 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

PHARMAC to fund dexamethasone ocular implants
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - October 1, 2017 Category: Drugs & Pharmacology Source Type: news

Childhood CAP: Would Adding Dexamethasone Hasten Recovery? Childhood CAP: Would Adding Dexamethasone Hasten Recovery?
Could steroids, in addition to antibiotics, bring about faster recovery in children with CAP and pleural effusion?Medscape Pediatrics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2017 Category: Consumer Health News Tags: Pediatrics Viewpoint Source Type: news

Lucky Mart Inc. Issues Voluntary Nationwide Recall Of Piyanping Anti-Itch Lotion Due to Incorrect Active Ingredient
Lucky Mart Inc. is voluntarily recalling lots C14005, C16001 and C16002 of Piyanping Anti-Itch Lotion to the consumer level. The product was manufactured using the active pharmaceutical ingredient dexamethasone rather than hydrocortisone. Dexamethasone is not listed as an ingredient in the labeling. (Source: Food and Drug Administration)
Source: Food and Drug Administration - August 30, 2017 Category: Food Science Source Type: news

Long-Term Analysis Of Phase 3 Head-To-Head Study Confirms KYPROLIS ® (Carfilzomib) Regimen Extends Overall Survival In Patients With Relapsed Multiple Myeloma
ENDEAVOR Study Long-Term Data Shows KYPROLIS and Dexamethasone Reduced the Risk of Death by 24 Percent Versus Velcade® (Bortezomib) and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 9.0 Months Longer Than Patients Receiving Velcade and Dexamethasone Long-Term Follow-Up Demonstrated Consistent Safety Profile THOUSAND OAKS, Calif., Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive results from a post-hoc analysis requested by the U.S. Food and Drug Administration (FDA) of the Phase 3 head-to-head ENDEAVOR trial, which followed patients for at least three y...
Source: Amgen News Release - August 30, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Accepts Amgen's Filing Of A Supplemental New Drug Application To Add Overall Survival Results To KYPROLIS ® (Carfilzomib) Label
FDA Sets PDUFA Target Action Date of April 30, 2018 THOUSAND OAKS, Calif., Aug. 30, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) based on the overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial demonstrating that KYPROLIS® (carfilzomib) and dexamethasone (Kd) reduced the risk of death by 21 percent and increased OS by 7.6 months versus Velcade® (bortezomib) and dexamethasone (Vd) in patients with relapsed or refractory multiple myeloma (median OS 47.6 mon...
Source: Amgen News Release - August 30, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Overall Survival Analysis From KYPROLIS ® (carfilzomib) Phase 3 Endeavor Trial Published In The Lancet Oncology
KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent Compared to Velcade® (bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients KYPROLIS is the First and Only Multiple Myeloma Therapy Proven to Extend Overall Survival in a Head-to-Head Comparison With a Current Standard of Care in the Relapsed Setting THOUSAND OAKS, Calif., Aug. 23, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that results from an overall survival (OS) analysis of the Phase 3 head-to-head ENDEAVOR trial were published online first in The Lancet Oncology. Data showed that KYPROLIS® (...
Source: Amgen News Release - August 23, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

At What Height Do You Consider Preventative Treatment for Acute Mountain Sickness?
Discussion Acute mountain sickness (AMS) is a well-known problem for some people who travel to high altitude, especially altitudes> 2500 m (~8200 feet). Symptoms include headache, nausea or emesis, shortness of breath, dizziness, fatigue, difficulty sleeping and poor appetite. The incidence in adults ranges from 25% at 2975 m to up to 75% at 5896 m. The incidence in children is less clear but it appears that children are more susceptible at 45% for 16-19 year olds for similar altitudes. Risk factors are numerous including age, gender, obesity, ascent rate, altitude for sleeping, previous exposure to high altitude, previ...
Source: PediatricEducation.org - August 21, 2017 Category: Pediatrics Authors: pediatriceducationmin Tags: Uncategorized Source Type: news

Reduced Retreatment Dose Feasible in Relapsed, Refractory Multiple Myeloma
Prolonged use of bortezomib after treatment with combined bortezomib plus dexamethasone did not result in any significant benefit for patients with relapsed/refractory multiple myeloma compared with bortezomib plus dexamethasone alone, but this less dose-intensive approach could be a feasible option for patients who cannot tolerate the standard regimen. (Source: CancerNetwork)
Source: CancerNetwork - August 19, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news

SMC approves Amgen ’s carfilzomib for multiple myeloma treatment
The Scottish Medicines Consortium (SMC) has approved the routine use of Amgen ’s carfilzomib (Kyprolis), in combination with dexamethasone, for the treatment of multiple myeloma across National Health Service (NHS) Scotland. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - August 8, 2017 Category: Pharmaceuticals Source Type: news

Droperidol + OND and DEX in Children for Postop Vomiting Droperidol + OND and DEX in Children for Postop Vomiting
The combination of dexamethasone, ondansetron, and droperidol has been shown to be effective in preventing postoperative nausea and vomiting in adults. Is it safe and effective for children?British Journal of Anaesthesia (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2017 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news

Amgen Submits Regulatory Applications In US And Europe To Include Overall Survival Data In KYPROLIS ® (Carfilzomib) Label
Data Showed KYPROLIS and Dexamethasone Reduced the Risk of Death by 21 Percent and Increased Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients THOUSAND OAKS, Calif., July 14, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) and a variation to the marketing application to the European Medicines Agency (EMA) to include overall survival (OS) data from the Phase 3 head-to-head ENDEAVOR trial in the product information fo...
Source: Amgen News Release - July 14, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen ’s multiple myeloma drug shows positive outcome in Phase III trial
Amgen has reported a positive outcome from the Phase III clinical trial (ASPIRE) of Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone (KRd) to treat relapsed multiple myeloma. (Source: Drug Development Technology)
Source: Drug Development Technology - July 13, 2017 Category: Pharmaceuticals Source Type: news

Second Phase 3 Study Shows KYPROLIS ® (Carfilzomib) Regimen Significantly Improves Overall Survival In Patients With Relapsed Multiple Myeloma
KYPROLIS, Lenalidomide and Dexamethasone Reduced the Risk of Death by 21 Percent Versus Lenalidomide and Dexamethasone Patients Treated With the KYPROLIS-Based Regimen Survived 7.9 Months Longer Than Patients on Lenalidomide and Dexamethasone KYPROLIS-Based Regimens Are the First and Only to Demonstrate Improved Overall Survival Versus Today's Standards of Care in Two Phase 3 Studies in Relapsed Multiple Myeloma THOUSAND OAKS, Calif., July 12, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced positive results from the final analysis of the Phase 3 ASPIRE trial. The study met the key secondary endpoint ...
Source: Amgen News Release - July 12, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Rapid, Durable Responses in Advanced Myeloma With Daratumumab Combo
Treatment with the combination of daratumumab plus pomalidomide/dexamethasone resulted in rapid, deep, and sustained responses with no new safety signals in patients with heavily treated multiple myeloma. (Source: CancerNetwork)
Source: CancerNetwork - July 12, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Hematologic Malignancies Multiple Myeloma News Source Type: news